Brace Pharma
Brace Pharma Capital is a U.S. strategic investment vehicle formed by Brazil's EMS S/A, deploying committed capital into clinical-stage biopharmaceutical companies developing therapies for diseases with high unmet medical need.
- Company typePrivate
- Founded2013
- HeadquartersRockville, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Brace Pharma does
Brace Pharma Capital is a privately held strategic investment company headquartered at 387 Technology Cir NW, Suite 225, Atlanta, Georgia, with its founding footprint at the Rockville Innovation Center in Maryland. The firm was established in 2013 by EMS S/A, Brazil's largest domestic pharmaceutical company, alongside high-net-worth biotech investors, to deploy an announced $200 million into clinical-stage biopharmaceutical companies developing therapies for diseases with high unmet medical need. Brace does not develop therapeutic technologies itself; instead, it provides equity capital across financing rounds to portfolio companies operating in gene therapy (AVROBIO), genome editing (Precision BioSciences), antibody-siRNA conjugates (Avidity Biosciences), bispecific antibodies (Zymeworks), cell therapy (Unum Therapeutics), antiviral and antifungal modalities (ReViral, F2G), and other clinical-stage programs. Its investment criteria include U.S. market potential above $200 million, commercial pathways compatible with a specialty sales force of up to 100 representatives, and at least seven years of remaining patent life or market exclusivity.
The firm is led by Vinzenz Ploerer, President and CEO, who concurrently holds board seats at multiple portfolio companies, and Dr. Raymond Schinazi, founder of Pharmasset (acquired by Gilead in 2012) and a pioneer in antiviral drug development, who serves on both the Board of Directors and the Scientific Advisory Board. Brace pursues deal sourcing through direct outreach, healthcare investment conference attendance (JP Morgan, Jefferies, Cowen, BIO, RESI, Leerink, Wedbush, H.C. Wainwright, UBS, Oppenheimer), and direct submission of non-confidential summaries via [email protected]. Its revenue mechanics are tied to capital appreciation on equity positions, dividends from portfolio companies, and exit proceeds from acquisitions or public offerings, rather than operating revenue, and the firm does not publicly disclose revenue.
Across 2014-2018, Brace participated in at least 12 syndicated financing rounds totaling more than $495 million in aggregate round sizes, leading rounds at Therabron Therapeutics (Series B, $6.75M), Navitor Pharmaceuticals (Series B, $33M), and Antiva Biosciences (Series C, $22M), and joining syndicates at Unum Therapeutics, Zymeworks, miRagen, ReViral, F2G, and Precision BioSciences. The portfolio spans the United States, the United Kingdom, and Canada-listed biotechs, indicating a cross-border deployment of U.S.-headquartered capital into clinical-stage therapeutic assets.
Brace Pharma firmographics
Firmographics- Name
- Brace Pharma
- Legal name
- Brace Pharma Capital
- Website
- http://www.bracepharma.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Brace Pharma Capital is a U.S. strategic investment vehicle formed by Brazil's EMS S/A, deploying committed capital into clinical-stage biopharmaceutical companies developing therapies for diseases with high unmet medical need.
- Ownership category
- akta.pro rank
Brace Pharma industry classification
Industry- Product category
- Life Sciences Venture Capital Investment
- NAICS
- Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
- akta.pro secondary industries
- Specialty Care Pharmaceuticals (HLAIAAAB), Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Access Policy, Advocacy & Stakeholder Management (HLAIAKAL)
Keywords
Where Brace Pharma is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Brace Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Investment Returns and Capital Gains: Brace Pharma Capital generates returns through equity investments in biopharmaceutical companies. As a strategic investment vehicle formed by EMS S/A, the firm invests in clinical-stage biotech companies with the goal of achieving capital appreciation through successful development and commercialization of innovative therapies, eventual exit through acquisition or public offering, and dividend income from portfolio companies.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Brace Pharma product offering
Product offeringCore offering
Brace Pharma Capital is a strategic investment company that provides equity capital and investment services to clinical-stage and pre-clinical biopharmaceutical companies developing innovative therapies for diseases with high unmet medical need. The firm invests across modalities including gene therapies, genome editing, bi-specific antibodies, antiviral and antifungal agents, and cellular immunotherapies, targeting therapies with potential to reach market in 3–7 years and meet defined investment criteria including U.S. revenue potential exceeding $200 million and at least 7 years of remaining patent life or market exclusivity.
Product overview
Brace Pharma Capital is a strategic investment company that provides capital and investment services to innovative biopharmaceutical companies. Rather than operating a unified software platform, Brace Pharma functions as an investment vehicle formed by EMS S/A (Brazil's largest pharmaceutical company) and high net-worth biotech investors. The company invests in clinical and pre-clinical stage biotech companies developing life-changing therapies across multiple therapeutic areas including oncology, infectious diseases, genetic disorders, and rare/orphan diseases. The investment portfolio includes 12 portfolio companies focused on diverse modalities including gene therapies, genome editing, bi-specific antibodies, antiviral drugs, and cellular immunotherapies.
Differentiator
Problem solved
Functional benefit
Products and services
- Brace Pharma Capital Investment Services Strategic equity investment services targeting innovative clinical-stage and pre-clinical biopharmaceutical companies developing life-changing therapies for diseases with high unmet medical need, with investments structured to enable therapies to reach market in 3–7 years.
Companies that use Brace Pharma
Customer profileSegments1 record
Ideal customer profiles1 record
Brace Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Brace Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NORD (National Organization for Rare Disorders)minorBrace became a member of NORD, a unique federation of voluntary health organizations dedicated to helping people with rare orphan diseases.
Scale indicators1 record
Recent moves8 records
Expansion highlights5 records
Brace Pharma competitors and assessment
Company assessmentDirect peers
- Roche Venture Fund: CVC arm of Roche investing in innovative therapeutics and diagnostics. Comparable as a long-duration pharma corporate investor backing clinical-stage biotech companies across diverse modalities.
- OrbiMed: Dedicated healthcare investment firm with $19B+ AUM. Frequently co-invests with Brace (e.g., ReViral Series A and B, F2G Series C), making it a directly comparable dedicated biotech investor.
- Pfizer Ventures: CVC arm of Pfizer investing across therapeutic areas and modalities. Highly comparable pharma-backed investor competing for similar clinical-stage biotech opportunities.
- Lilly Asia Ventures: CVC arm of Eli Lilly focused on life sciences investments. Comparable pharma-backed CVC with similar strategic investment mandate into innovative therapeutic platforms.
- Aisling Capital: Healthcare-focused venture capital firm. Co-invested with Brace in F2G Series C financing, operating in the same clinical-stage biotech investment space with comparable deal sizes.
- SR One (GlaxoSmithKline): Independent CVC backed by GSK, investing in biotech and emerging life science companies. Directly comparable strategic CVC model with similar focus on clinical-stage therapeutic platforms.
- New Leaf Venture Partners: Healthcare-focused venture capital firm. Co-invested with Brace in Unum Therapeutics Series B and ReViral Series B, representing directly comparable dedicated biotech investor.
- Novartis Venture Fund: Corporate venture capital arm of Novartis investing in early-stage life sciences companies. Directly comparable as a pharma-company-backed CVC deploying strategic capital into clinical-stage biotech, with similar modality-agnostic therapeutic focus.
Broad incumbents
- Atlas Venture: Established early-stage life sciences venture capital firm with broader portfolio scale and longer track record. Comparable as a clinical-stage biotech investor but operates as a traditional fund rather than corporate-backed vehicle.
- RA Capital Management: Dedicated healthcare investment firm with crossover fund capabilities. Comparable as a clinical-stage biotech investor with significantly larger AUM and broader therapeutic reach.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Brace Pharma social profiles
Digital presenceBrace Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Brace Pharma leadership team
Management profileNumber of profiles
Profiles2 records
Brace Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Brace Pharma M&A and investment
M&A and investmentM&A
Investments26 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Brace Pharma
What does Brace Pharma do?
Brace Pharma Capital is a strategic investment company that provides equity capital and investment services to clinical-stage and pre-clinical biopharmaceutical companies developing innovative therapies for diseases with high unmet medical need. The firm invests across modalities including gene therapies, genome editing, bi-specific antibodies, antiviral and antifungal agents, and cellular immunotherapies, targeting therapies with potential to reach market in 3–7 years and meet defined investment criteria including U.S. revenue potential exceeding $200 million and at least 7 years of remaining patent life or market exclusivity.
Is Brace Pharma a public or private company?
Brace Pharma is a private company. It is classified as corporate owned and is currently operating.
When was Brace Pharma founded?
Brace Pharma was founded in 2013. It employs 101 to 250 people.
Where is Brace Pharma based?
Brace Pharma is headquartered in Rockville, United States, in the North America region.
How does Brace Pharma make money?
One revenue line is on record: investment Returns and Capital Gains.
Who are Brace Pharma's main competitors?
Direct peers on record are Roche Venture Fund, OrbiMed, Pfizer Ventures, Lilly Asia Ventures, Aisling Capital, SR One (GlaxoSmithKline), New Leaf Venture Partners and Novartis Venture Fund. Broad incumbents are Atlas Venture and RA Capital Management.
Does Brace Pharma have an API?
No public API is recorded for Brace Pharma.
What industry is Brace Pharma in?
Brace Pharma's product category is Life Sciences Venture Capital Investment. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 523940 and its SIC code is 2834.